UroToday

ASTRO 2025: Discussant: Biomarker Breakthroughs in Prostate Cancer

(UroToday.com) The 2025 ASTRO annual meeting featured a biomarker breakthroughs prostate cancer session and a discussant presentation by Dr. Alan Dal Pra. Dr. Dal Pra noted that amongst the six ...
UroToday

ASTRO 2025: Testosterone Recovery post ADT in Intermediate Risk Prostate Cancer Patients: Does a Higher Dose of Radiotherapy Impact on Survival? Long-Term Data f…

In intermediate risk prostate cancer patients randomized to short-term ADT and either 70 Gy or 76 Gy, testosterone recovery ...
UroToday

ASTRO 2025: Validation of a Prognostic Multimodal Artificial Intelligence Model in Asian Prostate Cancer Patients from Singapore

(UroToday.com) The 2025 ASTRO annual meeting featured a predictive markers in prostate cancer session and a presentation by Dr. Melvin L. K. Chua discussing validation of a prognostic multimodal ...
UroToday

ASTRO 2025: Discordance of Adverse Molecular Features between the 22-Gene Genomic Classifier Score, Histologic Grade, and NCCN Risk Groups: Analysis of Over 200,000 Patients

The presence of adverse molecular features most closely correlated with genomic classifier scores, even within low grade tumors. There was an observed nearly 20-fold increase in the presence of ...